

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (date of earliest event reported): November 7, 2023**

**ARTERIS, INC.**

(Exact name of Registrant, as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**001-40960**  
(Commission File Number)

**27-0117058**  
(I.R.S. Employer Identification Number)

**900 E. Hamilton Ave., Suite 300  
Campbell, CA 95008**  
(Address of principal executive offices, including Zip code)

**Registrant's telephone number, including area code: (408) 470-7300**

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock, \$0.001 par value per share</b>	<b>AIP</b>	<b>The Nasdaq Stock Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On November 7, 2023, Arteris, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 and Item 9.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release dated November 7, 2023</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2023

**By:** /s/ Nicholas B. Hawkins  
**Name:** Nicholas B. Hawkins  
**Title:** Vice President and Chief Financial Officer  
*(Principal Financial and Accounting Officer)*



## Arteris Announces Financial Results for the Third Quarter 2023 and Fourth Quarter and Full Year 2023 Guidance

CAMPBELL, Calif. - November 7, 2023 - Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced financial results for the third quarter ended September 30, 2023 as well as fourth quarter and full year 2023 guidance.

"Customer demand remained healthy in the third quarter, with Annual Contract Value plus Trailing-Twelve-Month Royalties of \$57.3 million, up 8% year-over-year," said K. Charles Janac, President and CEO of Arteris. "With the majority of the top 10 semiconductor companies now at least initially engaged with Arteris, the industry's transition to commercial System IP products is gaining momentum. Many of these vendors have historically used internal System IP solutions, however as the complexities of SoCs continues to increase, including the incorporation of AI capabilities into future designs, the value of Arteris' commercial offerings is becoming readily apparent," concluded Janac.

### **Third Quarter 2023 Financial Highlights:**

- Annual Contract Value (ACV) and Trailing-twelve-month (TTM) variable royalties of \$57.3 million, up 8% year-over-year
- Revenue of \$13.3 million, up 5% year-over-year
- Remaining performance obligation (RPO) of \$62.5 million
- Operating loss of \$8.5 million or 63.7% of revenue
- Non-GAAP operating loss of \$4.5 million or 34.3% of revenue, compared to a loss of \$4.2 million in the year-ago period
- Net loss of \$8.2 million or \$0.23 per share
- Non-GAAP net loss of \$4.2 million or \$0.12 per share
- Non-GAAP free cash flow of \$(3.1) million or (23.7)% of revenue

### **Third Quarter 2023 Business Highlights:**

- Secured another major Active Customer, ranked as a top 10 global fabless semiconductor company;
- Continued strong design activity with 22 confirmed designs starts in the quarter, including 12 that enable AI technologies;
- Closed deals with three of the top 10 global technology companies, including one licensing FlexNoC 5;
- NeuReality deployed Arteris interconnect in its Inference Server's NR1 SoC, targeting generative AI, Large Language Models, and other AI workloads;
- AIChip selected Arteris interconnect for its ASIC Design Services targeting AI and Automotive SoCs;
- Fraunhofer IESE and Arteris have partnered to ensure interoperability between Arteris interconnect and Fraunhofer's DRAM subsystem design space exploration framework, supporting customers' highly differentiated and performance-optimized SoCs;
- Closed nine deals of FlexNoC 5 since its release in the second quarter of 2023, numerous prospects and evaluations pending; and
- Arteris innovation was recognized within the International Business Awards for "Technical Innovation of the Year" for Physically Aware NoCs and was also a recipient of the Autotech Breakthrough's "Autonomous Vehicle Technology of the Year" award, for innovation used in ADAS systems, combining AI and Automotive needs in its system IP technology.

**Fourth Quarter and Full Year 2023 Guidance:**

	<b>Q4 2023</b>	<b>FY 2023</b>
	(in millions, except %)	
<b>ACV + TTM royalties</b>	\$52.0 - \$56.0	\$52.0 - \$56.0
<b>Revenue</b>	\$11.3 - \$12.3	\$52.5 - \$53.5
<b>Non-GAAP operating loss (%)</b>	56.1% - 76.1%	39.0% - 44.0%
<b>Free cash flow (%)</b>	(52.4)% - (32.4)%	(38.1)% - (33.1)%

The guidance provided above are forward-looking statements and reflects Arteris' expectations as of today's date. Actual results may differ materially. Refer to the section titled "Forward-Looking Statements" below for information on the factors, among others, that could cause our actual results to differ materially from these forward-looking statements.

Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP operating loss, Non-GAAP operating loss margin, Non-GAAP net loss, Non-GAAP net loss per share, free cash flow and free cash flow margin are Non-GAAP financial measures. Additional information on Arteris' historic reported results, including a reconciliation of these Non-GAAP financial measures to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of Non-GAAP guidance measures reported above to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Arteris' results computed in accordance with GAAP.

Definitions of the other business metrics used in this press release including ACV, active customers, confirmed design starts and RPO are included below under the heading "Other Business Metrics."

**Conference Call**

Arteris will host a conference call today, November 7, 2023, to review its third quarter 2023 financial results and discuss its financial outlook.

Time:	4:30 PM ET
United States/Canada Toll Free:	1-888-886-7786
International Toll:	1-416-764-8658

A live webcast will also be available in the Investor Relations section of Arteris' website at: <https://ir.arteris.com/events-and-presentations>

A replay of the webcast will be available in the Investor Relations section of Arteris' website approximately two hours after the conclusion of the call and remain available for approximately 30 calendar days.

## **About Arteris**

Arteris is a leading provider of system IP for the acceleration of system-on-chip (SoC) development across today's electronic systems. Arteris network-on-chip (NoC) interconnect IP and SoC integration automation technology enable higher product performance with lower power consumption and faster time to market, delivering better SoC economics so its customers can focus on dreaming up what comes next. Learn more at [arteris.com](https://arteris.com).

© 2004-2023 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at <https://www.arteris.com/trademarks> are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

### **Investor Contacts:**

Arteris  
Nick Hawkins  
Chief Financial Officer  
[IR@arteris.com](mailto:IR@arteris.com)

Sapphire Investor Relations  
Erica Mannion and Michael Funari  
+1 617 542 6180  
[IR@arteris.com](mailto:IR@arteris.com)

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to, statements regarding our future financial and operating performance, including our GAAP and Non-GAAP guidance for the fourth quarter and full year 2023; our market opportunity and its potential growth; our position within the market and our ability to drive customer value; and our ability to make progress even in a challenging economic environment. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained herein are based on our historical performance and our current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent our expectations as of the date of this press release. Subsequent events may cause these expectations to change, and we disclaim any obligation to update the forward-looking statements in the future, except as required by law. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from our current expectations. Important factors that could cause actual results to differ materially from those anticipated in our forward-looking statements include, but are not limited to, the significant competition we face from larger companies and third-party providers; our history of net losses; whether semiconductor companies in the automotive market, enterprise computing market, communications market, consumer electronics market, and industrial markets incorporate our solutions into their end products and the growth and economic stability of these end markets; our ability to attract new customers and the extent to which our customers renew their subscriptions for our solutions; the ability of our customers' end products achieving market acceptance or growth; our ability to sustain or grow our licensing revenue; our ability, and the cost, to successfully execute on research and development efforts; the occurrence of product errors or defects in our solutions; if we fail to offer high-quality support; the occurrence of macro-economic conditions that adversely impact us, our customers and their end product markets; the effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine; the range of regulatory, operational, financial and political risks we are exposed to as a result of our dependence on international customers and operations; our ability to protect our proprietary technology and inventions through patents and other IP rights; whether we are subject to any liabilities or fines as a result of government regulation, including import, export and economic sanctions laws and regulations; the occurrence of a disruption in our networks or a security breach; risks associated with doing business in China; and the other factors described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 to be filed with the Securities and Exchange Commission (SEC) on November 7, 2023. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. Our results for the quarter ended September 30, 2023 are not necessarily indicative of our operating results for any future periods.

**Arteris, Inc.**  
**Condensed Consolidated Statements of Loss**  
(In thousands, except share and per share data)  
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Revenue				
Licensing, support and maintenance	\$ 12,084	\$ 11,135	\$ 36,926	\$ 35,743
Variable royalties and other	1,190	1,463	4,236	3,432
Total revenue	13,274	12,598	41,162	39,175
Cost of revenue	1,280	928	3,629	3,196
Gross profit	11,994	11,670	37,533	35,979
Operating expense:				
Research and development	10,997	11,022	34,465	30,849
Sales and marketing	5,024	4,411	15,630	12,788
General and administrative	4,426	3,991	13,331	12,138
Total operating expenses	20,447	19,424	63,426	55,775
Loss from operations	(8,453)	(7,754)	(25,893)	(19,796)
Interest expense	(77)	(22)	(136)	(60)
Other income (expense), net	898	340	2,641	406
Loss before income taxes and loss from equity method investment	(7,632)	(7,436)	(23,388)	(19,450)
Loss from equity method investment, net of tax	919	—	2,487	—
Provision for (benefit from) income taxes	(398)	248	453	722
Net loss	\$ (8,153)	\$ (7,684)	\$ (26,328)	\$ (20,172)
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.23)	\$ (0.23)	\$ (0.75)	\$ (0.63)
Weighted average shares used on computing per share amounts, basic and diluted	36,010,106	32,836,014	35,291,207	32,228,429



**Arteris, Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except share and per share data)  
(Unaudited)

	As of	
	September 30, 2023	December 31, 2022
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 18,627	\$ 37,423
Short-term investments	27,734	30,728
Accounts receivable, net	10,370	7,143
Prepaid expenses and other current assets	5,249	5,818
Total current assets	61,980	81,112
Property and equipment, net	5,430	3,617
Long-term investments	10,287	4,427
Equity method investment	9,410	11,897
Operating lease right-of-use assets	1,598	1,883
Intangibles, net	4,050	4,575
Goodwill	4,178	4,218
Other assets	5,238	3,787
<b>TOTAL ASSETS</b>	<b>\$ 102,171</b>	<b>\$ 115,516</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 445	\$ 572
Accrued expenses and other current liabilities	11,983	12,095
Operating lease liabilities, current	571	899
Deferred revenue, current	29,898	28,839
Vendor financing arrangements, current	1,623	1,264
Total current liabilities	44,520	43,669
Deferred revenue, noncurrent	22,647	21,840
Operating lease liabilities, noncurrent	1,038	1,009
Vendor financing arrangements, noncurrent	1,378	448
Deferred income, noncurrent	9,108	9,993
Other liabilities	1,451	1,022
Total liabilities	80,142	77,981
Stockholders' equity:		
Preferred stock, par value of \$0.001 - 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	—	—
Common stock, par value of \$0.001 - 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 36,826,655 and 34,625,875 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	37	34
Additional paid-in capital	114,652	103,778
Accumulated other comprehensive income	46	101
Accumulated deficit	(92,706)	(66,378)
Total stockholders' equity	22,029	37,535
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 102,171</b>	<b>\$ 115,516</b>

**Arteris, Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

	Nine Months Ended September 30,	
	2023	2022
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (26,328)	\$ (20,172)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	2,240	1,568
Stock-based compensation	10,981	9,082
Amortization of deferred income	(882)	(94)
Loss from equity method investment	2,487	—
Net accretion of discounts on available-for-sale securities	(698)	—
Gain on deconsolidation of subsidiary	—	(149)
Other, net	(3)	6
Changes in operating assets and liabilities:		
Accounts receivable, net	(3,225)	4,234
Prepaid expenses and other assets	(495)	(1,799)
Accounts payable	(237)	408
Accrued expenses and other liabilities	1,544	23
Deferred revenue	1,866	517
Net cash used in operating activities	<u>(12,750)</u>	<u>(6,376)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchases of property and equipment	(1,075)	(655)
Purchases of available-for-sale securities and other	(35,373)	(6,399)
Proceeds from maturities of available-for-sale securities	33,150	—
Payments relating to investment in equity method investment	—	(520)
Proceeds from principal portion of related party loan	—	241
Other	(25)	—
Net cash used in investing activities	<u>(3,323)</u>	<u>(7,333)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Payments of contingent consideration for business combination	(1,269)	(1,573)
Principal payments under vendor financing arrangements	(1,041)	(635)
Proceeds from exercise of stock options	460	601
Payments to tax authorities for shares withheld from employees	(564)	(2,053)
Payments of deferred offering costs	—	(256)
Other	79	—
Net cash used in financing activities	<u>(2,335)</u>	<u>(3,916)</u>
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(18,408)	(17,625)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period	37,423	85,825
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period	<u>\$ 19,015</u>	<u>\$ 68,200</u>

## **Non-GAAP Financial Measures**

To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors' overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define "Non-GAAP gross profit and Non-GAAP gross margin" as GAAP gross profit and GAAP gross margin, adjusted for stock-based compensation expense included in cost of revenue. We define "Non-GAAP Loss from Operations" as our income (loss) from operations adjusted to exclude stock-based compensation, acquisition costs and amortization of acquired intangible assets. We define "Non-GAAP Net Loss" as our net income (loss) adjusted to exclude stock-based compensation, acquisition costs, amortization of acquired intangible assets and gain on extinguishment of debt.

We define "Non-GAAP EPS", as our Non-GAAP Net Income (Loss) divided by our GAAP weighted-average number of shares outstanding for the period on a diluted basis. Management uses Non-GAAP EPS to evaluate the performance of our business on a comparable basis from period to period.

The above items are excluded from our Non-GAAP Gross Profit, Non-GAAP Income (Loss) from Operations and Non-GAAP Net Income (Loss) because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP Gross Profit, Non-GAAP Income (Loss) from Operations and Non-GAAP Net Income (Loss) provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance.

We define free cash flow as net cash (used in) provided by operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash used in our operations other than that used for investments in property and equipment.

## **Other Business Metrics**

**Active Customers** – we define Active Customers as customers who have entered into a license agreement with us that remains in effect. The retention and expansion of our relationships with existing customers are key indicators of our revenue potential.

**Annual Contract Value (ACV)** – we define Annual Contract Value (ACV) for an individual customer agreement as the total fixed fees under the agreement divided by the number of years in the agreement term. Our total ACV is the aggregate ACVs for all our customers as measured at a given point in time. Total fixed fees include licensing, support and maintenance and other fixed fees under IP licensing or software licensing agreements but exclude variable revenue derived from licensing agreements with customers, particularly royalties.

**Confirmed Design Starts** – we define Confirmed Design Starts as when customers confirm their commencement of new semiconductor designs using our interconnect IP and notify us. Confirmed Design Starts is a metric management uses to assess the activity level of our customers in terms of the number of new semiconductor designs that are started using our interconnect IP in a given period. We believe that the number of Confirmed Design Starts is an important indicator of the growth of our business and future royalty revenue trends.

**Remaining Performance Obligations (RPO)** – we define Remaining Performance Obligations (RPO) as the amount of contracted future revenue that has not yet been recognized, including deferred revenue, billed and unbilled cancelable and non-cancelable contracted amounts.

**Arteris, Inc.**  
**Reconciliation of GAAP Measures to Non-GAAP Measures**  
(In thousands, except share and per share data)  
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Gross profit	\$ 11,994	\$ 11,670	\$ 37,533	\$ 35,979
Stock-based compensation expense included in cost of revenue	181	118	386	474
Amortization of acquired intangible assets <sup>(1)</sup>	50	—	99	—
Non-GAAP gross profit	\$ 12,225	\$ 11,788	\$ 38,018	\$ 36,453
Gross margin	90 %	93 %	91 %	92 %
Non-GAAP gross margin	92 %	94 %	92 %	93 %
Research and development	\$ 10,997	\$ 11,022	\$ 34,465	\$ 30,849
Stock-based compensation expense	(1,742)	(1,798)	(5,656)	(4,435)
Amortization of acquired intangible assets <sup>(1)</sup>	(85)	(85)	(305)	(255)
Non-GAAP research and development	\$ 9,170	\$ 9,139	\$ 28,504	\$ 26,159
Sales and marketing	\$ 5,024	\$ 4,411	\$ 15,630	\$ 12,788
Stock-based compensation expense	(666)	(679)	(2,088)	(1,678)
Amortization of acquired intangible assets <sup>(1)</sup>	(57)	(34)	(171)	(103)
Non-GAAP sales and marketing	\$ 4,301	\$ 3,698	\$ 13,371	\$ 11,007
General and administrative	\$ 4,426	\$ 3,991	\$ 13,331	\$ 12,138
Stock-based compensation expense	(1,125)	(794)	(2,851)	(2,495)
Non-GAAP general and administrative	\$ 3,301	\$ 3,197	\$ 10,480	\$ 9,643
Loss from operations	\$ (8,453)	\$ (7,754)	\$ (25,893)	\$ (19,796)
Stock-based compensation expense	3,714	3,389	10,981	9,082
Amortization of acquired intangible assets <sup>(1)</sup>	192	119	575	358
Non-GAAP loss from operations	\$ (4,547)	\$ (4,246)	\$ (14,337)	\$ (10,356)
Net loss	\$ (8,153)	\$ (7,684)	\$ (26,328)	\$ (20,172)
Stock-based compensation expense	3,714	3,389	10,981	9,082
Amortization of acquired intangible assets <sup>(1)</sup>	192	119	575	358
Non-GAAP net loss <sup>(2)</sup>	\$ (4,247)	\$ (4,176)	\$ (14,772)	\$ (10,732)
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.23)	\$ (0.23)	\$ (0.75)	\$ (0.63)
Per share impacts of adjustments to net loss <sup>(3)</sup>	\$ 0.11	\$ 0.10	\$ 0.33	\$ 0.30
Non-GAAP EPS, basic and diluted	\$ (0.12)	\$ (0.13)	\$ (0.42)	\$ (0.33)
Weighted average shares used in computing per share amounts, basic and diluted	36,010,106	32,836,014	35,291,207	32,228,429

(1) Represents the amortization expenses of our intangible assets attributable to our acquisitions.

(2) Our GAAP tax provision is primarily related to foreign withholding taxes and income tax in profitable foreign jurisdictions. We maintain a full valuation allowance against our deferred tax assets in the US. Accordingly, there is no significant tax impact associated with these Non-GAAP adjustments.

(3) Reflects the aggregate adjustments made to reconcile Non-GAAP Net Loss to our net loss as noted in the above table, divided by the GAAP diluted weighted average number of shares of the relevant period.

## Free Cash Flow

	Nine Months Ended September 30,	
	2023	2022
	<i>(in thousands)</i>	
Net cash used in operating activities	\$ (12,750)	\$ (6,376)
Less:		
Purchases of property and equipment	(1,075)	(655)
Free cash flow	\$ (13,825)	\$ (7,031)
Net cash used in investing activities	\$ (3,323)	\$ (7,333)
Net cash used in financing activities	\$ (2,335)	\$ (3,916)